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The formation of multidisciplinary breast teams across the UK is intended to concentrate the assessment and treatment of breast
cancer into the hands of high volume specialists. We undertook a retrospective population-based study in order to determine the
trends in surgeon breast cancer workload in Yorkshire, UK, and to investigate whether patients treated by low-workload surgeons
had poorer survival. Of 11329 female breast cancer patients diagnosed in 1989–1994 in Yorkshire, 6% were managed by surgeons
with a mean annual workload of less than 10 new patients, while surgeons with workloads of 10–29, 30–49 and 450 treated 21, 21
and 52%, respectively. Over the study period, increasing number of patients were managed by surgeons with higher workloads.
Patients treated by low-workload surgeons had poorer survival. Five-year survival was 60% in the lowest workload category
compared to 68% in the highest category. The relative risk of death was increased by 15% (RR¼1.15, 95% CI 1.03–1.28) and by
10% (RR¼1.10, 95% CI 1.02–1.18) for patients managed by surgeons with workloads o10 and 10–29 cases per annum in
comparison to patients managed by surgeons with workloads of 450. The results of this study suggest increasing site specialisation in
breast cancer among general surgeons. It also provides further evidence that the management of patients by surgeons with low
workloads decreases overall survival.
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Despite evidence of improving mortality from breast cancer in the
UK (Peto et al, 2000), published studies suggest that survival from
breast cancer in the UK compares unfavourably with many
European countries (Quinn et al, 1998; Berrino et al, 1999). Wide
variations in the management of breast cancer patients have been
reported in the UK (Chouillet et al, 1994; Sainsbury et al, 1995b;
Richards et al, 1996), and variable care is thought to contribute to
the relatively poor performance in the UK (Sant et al, 1998).
Greater specialisation in the management of breast cancer, with the
formation of multidisciplinary teams, gradually followed the
implementation of breast screening 10–12 years ago. This was
further stimulated by a major national policy initiative in cancer in
1995 (Calman and Hine, 1995), and by the subsequent publication
of the Improving Outcomes Guidance for breast cancer services in
1996 (Cancer Guidance, 1996).
Whether better outcomes in breast cancer are directly related to
the concentration of breast cancer patients in the hands of
specialist surgeons, and the multidisciplinary teams in which they
work, has been a subject of growing interest. Although significant
outcome benefits from higher caseloads for complex radical cancer
surgery, such as in pancreatic or prostate cancer, have been
reported, the evidence for caseload outcome relationships in
cancers requiring low-risk surgery, like breast cancer, is based on
far fewer studies (Hillner et al, 2000).
In this study, our aim was to follow-up an earlier investigation
on the effect of surgeon workload on survival of breast cancer
patients (Sainsbury et al, 1995a), and to establish whether the
original finding, supportive of a volume outcome relationship, has
remained the case in a more recent time period. We also wished to
examine how surgeons’ breast cancer workloads have changed
over time and to assess whether differences in outcome could be
explained by case-mix and treatment regimes employed.
MATERIALS AND METHODS
All female breast cancer patients diagnosed in the former
Yorkshire Regional Health Authority area between 1989 and
1994 were identified from the Northern and Yorkshire Cancer
Registry and Information Service (NYCRIS) database (n¼12, 338).
Patients treated outside the region, those registered on the basis of
information available from death certificates only, and some
private patients were excluded because of the insufficient clinical
management details (n¼520). The total number of patients
eligible for the study was 11818.
Relevant patient characteristics and treatment details were
abstracted from the cancer registry database. Socioeconomic
status was determined using small-area data on socioeconomic
classification from Super Profiles, a tool created by clustering
together socially similar enumeration districts (Aveyard et al,
2000). The surgeon workloads were calculated as the mean number
of new breast cancer patients managed per practising year. Patients
were divided into four categories according to their surgeon
annual workload (very low workload category of o10, low
category 10–29, moderate 30–49 and high workload category
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lwith 450 average annual new cases). The mean annual hospital
workload categories were estimated taking into account new
consultant posts and retirements during the study period.
Data analysis
The survival period for each patient was calculated as the time
difference between the date of diagnosis (taken as date of first
hospital visit) and the date of death or censoring (1 January 2002).
The overall relative survival and the relative survival for each
factor (disease extent, treatment modality, type of surgery,
socioeconomic status, time period, surgeon and hospital work-
load) were estimated using the Kaplan–Meier method. Cox’s
proportional hazards model was applied to estimate the relative
risk of death (Cox, 1972). Estimates were initially considered for
each factor in isolation, and then all case-mix factors (age, disease
extent, tumour grade, socioeconomic status and time period) were
included in the regression model. Finally, the relative risks of death
were adjusted for all factors together, including treatment, surgeon
workload and hospital volume.
We have compared our findings with the results of an earlier
study that investigated the influence of surgeon workload on
survival from breast cancer in Yorkshire for the period 1979–1988
(Sainsbury et al, 1995a). That study was based on data from the
same cancer registry and covered the population of the same
region (the former Yorkshire Regional Health Authority area). The
same workload categories have been used, and the same statistical
methods applied. We used the original data from the earlier study
to re-estimate the relative risks of death with the high-workload
group as a base category in order to show the disadvantage
associated with being managed by low-workload surgeon.
RESULTS
Over the study period, 95 surgeons were involved in the
management of 96% of the study population (n¼11329), either
with or without additional involvement of a consultant from
another specialty. One-third (36.9%) of all cases were managed
solely by a surgeon.
Overall, surgeons with a mean annual workload of less than 10
managed just 6% (n¼702) of the study population (Table 1).
Surgeons with a workload of 10–29 and 30–49 treated the same
proportion of cases (21%), while the high-workload surgeons
managed 52%. The proportion of patients treated by surgeons with
workload of more than 30 has increased steadily during the study
period from 66% in 1989–1990 to 79% in 1993–1994 (Table 1),
what is a substantial increase over the 45% during the early and
mid-1980s (Table 2). The overall number of surgeons that were
treating breast cancer patients in the region fell from 180 in 1979–
1988 to 95 in 1989–1994. In 1989–1994, 47 (49%) of the 95
surgeons were in the o10 category, compared with 67% in 1979–
1988. A total of 11 surgeons were treating 450 patients per year in
1989–1994.
There were no significant differences in the type of surgery
(mastectomy vs breast-conserving surgery) by workload category
(Table 3). The use of chemotherapy was the only treatment
modality strongly correlated with consultant workload. Che-
motherapy rates increased from 12% in the very low workload
category to 21% in the high category. Patients managed by
surgeons with an annual workload over 30 were less likely to be
treated by surgery alone and more likely to receive multimodality
primary treatment (surgery combined with radiotherapy, che-
motherapy and/or hormone therapy) (Table 3).
There were large differences between hospital trusts in the
proportions of patients managed by surgeons in each workload
category. Surgeons in the highest workload category (450 cases
per annum) managed nearly all patients (98.8%) in one trust in
contrast to six other hospital trusts (out of 17 in total) where no
surgeons worked at that caseload level.
The overall survival 5 years after diagnosis was 66%. Patients
treated by higher workload surgeons had better survival. The 5-
year survival was 60% in the lowest surgeon workload category, 64
and 66% in the intermediate categories and 68% in the highest
workload category. Multivariate analysis confirmed the survival
advantage for patients treated by moderate- and high-workload
surgeons. Compared to a baseline of 1.00 for patients treated by
surgeons with the high workload, the relative risk of death
increased to 1.01, 1.10 and 1.15 in each subsequent category after
adjusting for all recorded case-mix factors and treatment (Table 4).
For the workload categories 10–29 and less than 10, the relative
risks of death were similar to those described in the earlier paper
(Table 2). The effect of surgeon workload on survival contrasted
with the absence of any significant hospital workload effect.
Patient age significantly influenced survival, with the relative
risk of death increasing with increasing age (Table 4). Patients with
more advanced disease (positive axillary lymph nodes or
metastases) and less-well-differentiated tumours had poorer
Table 1 Number (percentage) of patients in each workload category by time period
Surgeon workload 1989–1990 1991–1992 1993–1994 Overall
o10 359 (10.0%) 199 (5.1%) 144 (3.7%) 702 (6.2%)
10–29 882 (24.5%) 790 (20.5%) 677 (17.5%) 2349 (20.7%)
30–49 756 (21.0%) 774 (20.1%) 830 (21.4%) 2360 (20.8%)
50+ 1602 (44.5%) 2091 (54.3%) 2225 (57.4%) 5918 (52.2%)
Total 3599 (31.8%) 3854 (34.0%) 3876 (34.2%) 11329 (100%)
Table 2 Proportion of patients and consultants in each workload category and results of the adjusted relative risks of death compared with the earlier
study





o10 10% 6% 67% 49% 1.16 (1.06–1.27) 1.15 (1.03–1.28)
10–29 45% 21% 24% 27% 1.14 (1.07–1.21) 1.10 (1.02–1.18)
30–49 15% 21% 5% 12% 0.98 (0.90–1.05) 1.01 (0.93–1.08)
50+ 30% 52% 4% 12% 1.00 1.00
aSource: Sainsbury et al (1995).
bFigures based on the above paper (see Materials and methods section).
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lTable 3 Number (percentage) of patients in each workload category by type of surgery and adjuvant therapy received
Workload
o10 10–29 30–49 50+ All
Surgery type
BCS alone 294 (41.9%) 757 (32.2%) 958 (40.6%) 2178 (36.8%) 4187 (37.0%)
Mastectomy alone 246 (35.0%) 971 (41.3%) 743 (31.5%) 2272 (38.4%) 4232 (37.4%)
BCS & M 75 (10.7%) 332 (14.1%) 332 (14.1%) 854 (14.4%) 1593 (14.1%)
Treatment modalities received in addition to surgery
Radiotherapy 298 (42.5%) 1112 (47.3%) 1207 (51.1%) 2769 (46.8%) 5386 (47.5%)
Chemotherapy 85 (12.1%) 255 ((10.9%) 397 (16.8%) 1226 (20.7%) 1963 (17.3%)
Hormone therapy 498 (70.9%) 1606 (68.4%) 1606 (68.1%) 4256 (71.9%) 7966 (70.3%)
RT+CT/HT 268 (38.2%) 944 (40.2%) 1083 (45.9%) 2536 (42.9%) 4831 (42.6%)
Surgery alone 71 (10.1%) 218 (9.3%) 218 (9.2%) 481 (8.1%) 988 (8.7%)
BCS¼breast-conserving surgery; M¼mastectomy; S¼surgery; CT¼chemotherapy; RT¼radiotherapy and HT¼hormone therapy.
Table 4 Relative risk of death (95% confidence intervals)
Relative risk ratios
Each factor alone Allowing for case-mix factors Allowing for all factors
Case-mix
Age (years) o50 1.00 1.00 1.00
50–64 1.06 (0.97–1.15) 1.12 (1.03–1.22) 1.25 (1.14–1.36)
65–74 1.86 (1.70–2.02) 1.88 (1.73–2.05) 2.01 (1.82–2.22)
75+ 3.64 (3.35–3.95) 3.71 (3.41–4.02) 3.24 (2.92–3.60)
Extent of disease No known nodes/metastases
Nodal involvement
1.00 1.00 1.00
1.67 (1.58–1.77) 1.77 (1.67–1.88) 1.80 (1.70–1.92)
Metastases 7.81 (7.13–8.55) 6.58 (6.00–7.20) 5.16 (4.67–5.69)
Tumour grade (differentiation) Well 1.00 1.00 1.00
Moderately 1.51 (1.32–1.73) 1.40 (1.22–1.61) 1.42 (1.23–1.63)
Poor 2.53 (2.22–2.87) 2.34 (2.06–2.66) 2.21 (1.94–2.52)
Not known 2.35 (2.07–2.67) 2.09 (1.84–2.38) 1.65 (1.45–1.88)
Socioeconomic status 1–3 (affluent) 1.00 1.00 1.00
4–7 1.17 (1.09–1.25) 1.10 (1.03–1.17) 1.07 (1.00–1.15)
8–10 (deprived) 1.32 (1.22–1.43) 1.26 (1.16–1.36) 1.22 (1.13–1.33)
Time period 1989–1990 1.00 1.00 1.00
1991–1992 0.98 (0.93–1.04) 0.93 (0.87–0.99) 0.92 (0.86–0.98)
1993–1994 0.85 (0.80–0.90) 0.93 (0.87–1.00) 0.88 (0.82–0.94)
Treatment
Treatment S+R+C+H 1.00 1.00 1.00
S+R+C 1.14 (0.95–1.37) 1.17 (0.98–1.41) 1.17 (0.98–1.41)
S+R+H 0.89 (0.79–0.99) 0.76 (0.68–0.86) 0.75 (0.67–0.85)
S+R 0.72 (0.61–0.86) 0.81 (0.68–0.96) 0.79 (0.67–0.95)
S+C+H 1.12 (0.94–1.32) 1.13 (0.95–1.34) 1.14 (0.96–1.35)
S+C 1.01 (0.78–1.30) 1.02 (0.79–1.32) 1.03 (0.80–1.32)
S+H 1.05 (0.94–1.17) 0.80 (0.70–0.90) 0.79 (0.70–0.89)
S 0.80 (0.69–0.92) 0.77 (0.67–0.90) 0.78 (0.67–0.90)
R+C+H 6.07 (4.50–8.19) 2.69 (1.98–3.66) 2.67 (1.96–3.63)
R+C 9.25 (5.21–16.42) 6.58 (3.69–11.72) 6.46 (3.62–11.50)
R+H 4.66 (3.84–5.65) 1.49 (1.20–1.83) 1.47 (1.19–1.82)
R 1.56 (0.86–2.83) 1.01 (0.55–1.84) 1.00 (0.55–1.82)
C+H 8.46 (6.35–11.27) 3.52 (2.62–4.72) 3.54 (2.64–4.76)
C 2.98 (1.41–6.29) 1.75 (0.83–3.70) 1.75 (0.83–3.70)
H 4.53 (4.02–5.10) 2.18 (1.89–2.52) 2.19 (1.90–2.53)
None 8.42 (6.49–10.92) 5.22 (3.98–6.86) 5.28 (4.02–6.94)
Workload
Surgeon Workload (cases per year) 50+ 1.00 1.00 1.00
30–49 1.08 (1.01–1.16) 1.06 (0.99–1.14) 1.01 (0.93–1.08)
10–29 1.20 (1.12–1.28) 1.05 (0.98–1.13) 1.10 (1.02–1.18)
o10 1.27 (1.14–1.41) 1.10 (0.99–1.23) 1.15 (1.03–1.28)
Hospital Workload (cases per year) 100+ 1.00 1.00 1.00
70–99 1.01 (0.94–1.08) 1.00 (0.93–1.07) 1.02 (0.95–1.10)
50–69 1.05 (0.97–1.13) 1.02 (0.95–1.10) 1.06 (0.97–1.14)
o50 0.94 (0.86–1.01) 0.99 (0.91–1.08) 0.95 (0.87–1.03)
S¼surgery; CT¼chemotherapy; RT¼radiotherapy and HT¼hormone therapy.
Surgeon workload and breast cancer
JS Mikeljevic et al
489








lsurvival. Socioeconomic status also influenced the survival of
breast cancer patients with the least advantaged group having a
significantly increased risk of death (1.22 (95% CI 1.13–1.33))
compared to the most advantaged. Survival improved gradually
over the study period. Compared to the baseline of 1.00 for
patients treated in 1989 and 1990, relative risk reduced to 0.92
(0.86–0.98) for those treated between 1991 and 1992, and down to
0.88 (0.82–0.94) in the most recent period (1993–1994).
All treatment combinations in which surgery was not performed
did poorly, while most combinations of treatment that included
surgery were not statistically significant from the base category.
The only exception was the observation that patients who had
surgery and adjuvant radiotherapy and/or hormone therapy had a
lower relative risk than those in whom chemotherapy was given.
DISCUSSION
This study provides further evidence to support the hypothesis that
management by high-workload surgeons improves overall survival
from breast cancer. Patients managed by surgeons with workloads
less than 30 new cases per year had a 4% lower survival at 5 years
and a 10% increase in the relative risk of death in comparison to
management by high-workload surgeons (more than 50 new cases
year
 1). This is consistent with the previously described findings for
the 1979–1988 time period (Sainsbury et al, 1995a). The survival
disadvantage could not be explained by any differences in the case-
mix or treatment patterns in both studies and has remained
consistent across this population for 16 years. During that period
(1979–1994), there was a significant increase in the proportion of
patients treated by high-workload surgeons and improvement of the
overall 5-year survival from 63% (YCO, 1995) to 66%.
The current UK policy recommendation for specialist breast
cancer teams is that every team should see at least 100 new cases
per year (Calman and Hine, 1995). This guidance supports surgical
specialisation and team working but does not define a lower
threshold for new breast cancer cases per individual clinician. This
may be attributable to the scarcity of evidence on the relationship
between surgical caseloads and outcomes for this disease. There is
evidence available from other large observational studies support-
ing both hospital caseload (Roohan et al, 1998) and surgical
specialisation (Gillis and Hole, 1996) as important determinants of
better survival in relation to breast cancer.
This was an observational population-based study of all breast
cancer cases diagnosed within a defined geographical area covered
by the regional cancer registry. One advantage of large-scale
observational methods is that potential biases that may operate in
small studies are minimised when large numbers of cases are
examined on a population basis (Haward and Forman, 1996). More
accurate and unbiased assessment of the relationship between
volume and outcome could be obtained if the data could be
adjusted for other important case-mix variables that influence
outcomes (Devenport et al, 1996). In this study, we included all
breast cancer cases diagnosed within a population of over 3.6
million, and estimated the relative risk of death in relation to
surgical workload after adjusting for a range of patient factors of
established importance. While these factors were less comprehen-
sive than the ideal, particularly the completeness of the assessment
of extent of disease, there is no reason to believe that these
weaknesses could bias such a large population sample in relation
to surgeon caseloads. For this to occur would require primary care
physicians to selectively refer more severe breast cancer cases (i.e.,
those with worse prognostic features) to lower caseload surgeons.
Given that primary care physicians generally refer only suspected
cases (without the benefit of detailed mammographic assessment
and histology) for diagnosis and assessment, with a ratio of at least
10 without malignant disease for every cancer diagnosed, such
systematic bias seems implausible. The converse, whereby
potentially more serious cases were referred to specialists seems
more probable and, if this factor could be adjusted for, would
increase the magnitude of our observed effect.
The proportion of cases treated in Yorkshire by surgeons who
managed more than 30 new breast cancer patients per year
increased from 45% in 1979–1988 to 73% in 1989–1994. Increased
breast cancer incidence coupled with more subspecialisation
among general surgeons are the most likely causes for this
increase. The increasing proportion of patients managed by
surgeons with high breast workloads suggests the trend towards
subspecialisation among surgeons began before this became an
explicit recommendation following the Calman–Hine policy
initiative. However, this early trend was not consistent within the
Yorkshire region where large differences were found in the
proportions of patients managed by surgeons in each workload
category according to the NHS trust where they received their care.
It was not possible from our data to determine whether high-
workload surgeons have better outcomes because large caseloads
enable them to enhance particular surgical skills or because larger
volumes increase their expertise in breast cancer management,
using all treatment modalities more appropriately. However, our
data showed that patients managed by surgeons with higher
workloads received proportionally more chemotherapy and were
more likely to receive the combination of radiotherapy and other
adjuvant therapies. Chemotherapy and hormone therapy have
been repeatedly demonstrated to reduce the risk of local
recurrence (EBCTCG, 1992) and improve survival in appropriate
patients (EBCTCG, 1998; Aapro, 2001), although the overall use of
chemotherapy during the study period was low. The information
on local recurrence was not available in this study but there is
evidence that specialisation reduces the risk of local recurrence
due to increased use of systemic therapy (Golledge et al, 2000). The
negative impact of chemotherapy in the multivariate analysis was
most likely to have been due to the selection of the poorest
prognosis individual patients for this treatment during the period
in question. This predates the more general application of
chemotherapy protocols to groups of patients at higher risk,
which are now in use. The increased use of combined adjuvant
therapy by high-workload surgeons strongly suggests a multi-
disciplinary approach and input in the management of their breast
cancer patients. In contrast, low-workload surgeons were likely to
neither interact with medical and clinical oncologists nor attend
multidisciplinary meetings. It is also probable (although we have
no data to confirm this) that their surgical skills in achieving
complete excision were not as good as the experienced surgeon.
There are data from Edinburgh indicating that experienced
surgeons achieved higher rates of complete excision and had
lower mastectomy rates for cases of DCIS (Mr M Dixon, Western
General Hospital, personal communication).
During the 16-year period, surgeons with high workload treated
progressively more breast cancer patients and there was an
improvement in survival rates over the same period. Although a
number of factors are likely to have contributed to this improved
survival including advances in diagnosis and treatment as well as
better organisation of care, we confirmed that surgeon workload
does have a significant effect. These results support our earlier
findings, and provide further evidence of the benefits that follow
greater surgical specialisation within the context of moves towards
more multidisciplinary organisation of breast cancer services.
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